Format

Send to

Choose Destination
Bull Cancer. 2015 Jun;102(6):497-500. doi: 10.1016/j.bulcan.2015.04.014. Epub 2015 May 28.

[Molecular biology of castration-resistant prostate cancer].

[Article in French]

Author information

1
AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, UFR de médecine, 75890 Paris cedex 18, France. Electronic address: ludovic.doucet@aphp.fr.
2
AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France; Université Paris-Diderot, UFR de médecine, 75890 Paris cedex 18, France.
3
AP-HP, hôpital Saint-Louis, service d'oncologie médicale, 1, avenue Claude-Vellefaux, 75010 Paris, France.

Abstract

Castration-resistant prostate cancer was subjected to a paradigm switch from hormone resistance to androgen deprivation therapy resistance during the last decade. Indeed, new therapeutics targeting the androgen receptor showed clinical efficacy in patients with progressive disease under castration. Thus, it is a proof that the AR remains a dominant driver of oncogenesis in earlier-called hormone resistant prostate cancer. This review summarizes the molecular mechanisms involved in castration-resistant prostate cancer.

KEYWORDS:

Androgen receptor; Biologie moléculaire; Cancer de la prostate; Castration resistance; Molecular biology; Prostate cancer; Récepteur aux androgènes; Résistance à la castration

PMID:
26028493
DOI:
10.1016/j.bulcan.2015.04.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center